CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features ...

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

Users should always confirm readings and trend on the Dexcom G7 app or receiver before making treatment decisions. * Separate Dexcom Follow app and internet connection required.